Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Status: Enrolling
Updated:  11/20/2015
Clinical Research Facility
mi
from
Bellaire, TX
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Status: Enrolling
Updated: 11/20/2015
Clinical Research Facility
mi
from
Bellaire, TX
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Status: Enrolling
Updated:  11/20/2015
Clinical Research Facility
mi
from
Dallas, TX
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Status: Enrolling
Updated: 11/20/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Status: Enrolling
Updated:  11/20/2015
Clinical Research Facility
mi
from
Webster, TX
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Status: Enrolling
Updated: 11/20/2015
Clinical Research Facility
mi
from
Webster, TX
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Status: Enrolling
Updated:  11/20/2015
Clinical Research Facility
mi
from
Norfolk, VA
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Status: Enrolling
Updated: 11/20/2015
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Status: Enrolling
Updated:  11/20/2015
Clinical Research Facility
mi
from
Richmond, VA
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Status: Enrolling
Updated: 11/20/2015
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Status: Enrolling
Updated:  11/20/2015
Clinical Research Facility
mi
from
Spokane, WA
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Status: Enrolling
Updated: 11/20/2015
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Status: Enrolling
Updated:  11/20/2015
Clinical Research Facility
mi
from
Clarksburg, WV
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Status: Enrolling
Updated: 11/20/2015
Clinical Research Facility
mi
from
Clarksburg, WV
Click here to add this to my saved trials
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Status: Enrolling
Updated:  11/20/2015
mi
from
Camperdown,
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3
Status: Enrolling
Updated: 11/20/2015
mi
from
Camperdown,
Click here to add this to my saved trials
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/24/2015
California Dermatology and Clinical Research Institute
mi
from
Encinitas, CA
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/24/2015
California Dermatology and Clinical Research Institute
mi
from
Encinitas, CA
Click here to add this to my saved trials
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/24/2015
Encino Research Center T. Joseph Raoof MD, Inc.
mi
from
Encino, CA
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/24/2015
Encino Research Center T. Joseph Raoof MD, Inc.
mi
from
Encino, CA
Click here to add this to my saved trials
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/24/2015
Redwood Dermatology Research
mi
from
Santa Rosa, CA
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/24/2015
Redwood Dermatology Research
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/24/2015
Bettencourt Skin Center
mi
from
Henderson, NV
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/24/2015
Bettencourt Skin Center
mi
from
Henderson, NV
Click here to add this to my saved trials
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/24/2015
Academic Dermatology Associates
mi
from
Albuquerque, NM
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/24/2015
Academic Dermatology Associates
mi
from
Albuquerque, NM
Click here to add this to my saved trials
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/24/2015
Dermatology Consulting Services
mi
from
High Point, NC
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/24/2015
Dermatology Consulting Services
mi
from
High Point, NC
Click here to add this to my saved trials
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/24/2015
Paddington Testing Company
mi
from
Philadelphia, PA
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/24/2015
Paddington Testing Company
mi
from
Philadelphia, PA
Click here to add this to my saved trials
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/24/2015
Tennessee Clinical Research Center
mi
from
Nashville, TN
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/24/2015
Tennessee Clinical Research Center
mi
from
Nashville, TN
Click here to add this to my saved trials
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/24/2015
DermResearch, Inc.
mi
from
Austin, TX
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/24/2015
DermResearch, Inc.
mi
from
Austin, TX
Click here to add this to my saved trials
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/24/2015
University of Texas Health Science Center at Houston
mi
from
Houston, TX
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/24/2015
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/24/2015
Center for Clinical Studies, LTD, LLP
mi
from
Houston, TX
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/24/2015
Center for Clinical Studies, LTD, LLP
mi
from
Houston, TX
Click here to add this to my saved trials
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated:  11/24/2015
Suzanne Bruce and Associates, PA The Center for Skin Research Katy/Cinco Ranch
mi
from
Katy, TX
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
Status: Enrolling
Updated: 11/24/2015
Suzanne Bruce and Associates, PA The Center for Skin Research Katy/Cinco Ranch
mi
from
Katy, TX
Click here to add this to my saved trials
Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis
Phase 1, Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  11/24/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis
Phase 1, Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 11/24/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/1/2015
Novartis Investigative Site
mi
from
Pasadena, CA
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/1/2015
Novartis Investigative Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/1/2015
Novartis Investigative Site
mi
from
Indianapolis, IN
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/1/2015
Novartis Investigative Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/1/2015
Novartis Investigative Site
mi
from
St. Louis, MO
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/1/2015
Novartis Investigative Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/1/2015
Novartis Investigative Site
mi
from
East Windsor, NJ
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/1/2015
Novartis Investigative Site
mi
from
East Windsor, NJ
Click here to add this to my saved trials
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/1/2015
Novartis Investigative Site
mi
from
Verona, NJ
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/1/2015
Novartis Investigative Site
mi
from
Verona, NJ
Click here to add this to my saved trials
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/1/2015
Novartis
mi
from
New York, NY
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/1/2015
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/1/2015
Novartis Investigative Site
mi
from
Rochester, NY
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/1/2015
Novartis Investigative Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/1/2015
Novartis Investigative Site
mi
from
High Point, NC
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/1/2015
Novartis Investigative Site
mi
from
High Point, NC
Click here to add this to my saved trials
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/1/2015
Novartis Investigative site
mi
from
Dallas, TX
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/1/2015
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/1/2015
Novartis Investigative Site
mi
from
Houston, TX
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/1/2015
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/1/2015
Novartis Investigative Site
mi
from
Norfolk, VA
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/1/2015
Novartis Investigative Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/1/2015
Novartis Investigator Site
mi
from
Birmingham, AL
Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients
Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/1/2015
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Trial of CF101 to Treat Patients With Psoriasis
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/1/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Trial of CF101 to Treat Patients With Psoriasis
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/1/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Trial of CF101 to Treat Patients With Psoriasis
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated:  12/1/2015
UMHAT "G.stranski"
mi
from
Pleven,
Trial of CF101 to Treat Patients With Psoriasis
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Enrolling
Updated: 12/1/2015
UMHAT "G.stranski"
mi
from
Pleven,
Click here to add this to my saved trials
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/4/2015
Achieve Clinical Research
mi
from
Birmingham, AL
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/4/2015
Achieve Clinical Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/4/2015
Desert Medical Advances
mi
from
Palm Desert, CA
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/4/2015
Desert Medical Advances
mi
from
Palm Desert, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/4/2015
Bay Area Arthritis and Osteoporosis
mi
from
Brandon, FL
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/4/2015
Bay Area Arthritis and Osteoporosis
mi
from
Brandon, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/4/2015
Health Point Medical Group
mi
from
Brandon, FL
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/4/2015
Health Point Medical Group
mi
from
Brandon, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/4/2015
Palmetto Medical Research
mi
from
Hialeah, FL
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/4/2015
Palmetto Medical Research
mi
from
Hialeah, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/4/2015
Suncoast Clinical Research, Inc.
mi
from
New Port Richey, FL
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/4/2015
Suncoast Clinical Research, Inc.
mi
from
New Port Richey, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/4/2015
University of South Florida
mi
from
Tampa, FL
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/4/2015
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/4/2015
Coeur D'Alene Arthritis Clinic
mi
from
Coeur D'Alene, ID
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/4/2015
Coeur D'Alene Arthritis Clinic
mi
from
Coeur D'Alene, ID
Click here to add this to my saved trials
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/4/2015
Rockford Orthopedic Associates, LTD
mi
from
Rockford, IL
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/4/2015
Rockford Orthopedic Associates, LTD
mi
from
Rockford, IL
Click here to add this to my saved trials
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/4/2015
Advanced Rheumatology
mi
from
Lansing, MI
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/4/2015
Advanced Rheumatology
mi
from
Lansing, MI
Click here to add this to my saved trials
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/4/2015
Heartland Clinical Research, Inc.
mi
from
Omaha, NE
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/4/2015
Heartland Clinical Research, Inc.
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/4/2015
Physician's East
mi
from
Greenville, NC
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/4/2015
Physician's East
mi
from
Greenville, NC
Click here to add this to my saved trials
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/4/2015
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/4/2015
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/4/2015
West Tennessee Research Institute
mi
from
Jackson, TN
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/4/2015
West Tennessee Research Institute
mi
from
Jackson, TN
Click here to add this to my saved trials
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/4/2015
Ramesh C. Gupta, M.D.
mi
from
Memphis, TN
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/4/2015
Ramesh C. Gupta, M.D.
mi
from
Memphis, TN
Click here to add this to my saved trials